Systemic Lupus Erythematosus - Pipeline Review, H1 2018
Systemic Lupus Erythematosus - Pipeline Review, H1 2018
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Lupus Erythematosus - Pipeline Review, H1 2018, provides an overview of the Systemic Lupus Erythematosus (Immunology) pipeline landscape.
"Systemic lupus erythematosus (SLE) is an autoimmune disease that causes a chronic inflammatory condition. The inflammation triggered by SLE affect many organs in the body, including skin, joints, kidneys, brain, and other organs. Several factors have been associated with the disease such as genetics, environment and gender and hormones. Symptoms can vary and can change over time. Common symptoms include severe fatigue, painful or swollen joints, headaches, rash on cheeks and nose called butterfly rash, hair loss and anemia."
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Systemic Lupus Erythematosus - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Systemic Lupus Erythematosus (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Systemic Lupus Erythematosus (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Lupus Erythematosus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 10, 30, 25, 41, 5 and 3 respectively. Similarly, the Universities portfolio in Phase II, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1, 8 and 1 molecules, respectively.
Systemic Lupus Erythematosus (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Lupus Erythematosus (Immunology).
- The pipeline guide reviews pipeline therapeutics for Systemic Lupus Erythematosus (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Systemic Lupus Erythematosus (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Systemic Lupus Erythematosus (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Lupus Erythematosus (Immunology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Systemic Lupus Erythematosus (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned in the Report
AbbVie Inc
ACEA Biosciences Inc
AiCuris GmbH & Co KG
Amgen Inc
Apellis Pharmaceuticals Inc
Araim Pharmaceuticals Inc
Asahi Kasei Pharma Corp
Atlantic Bio Sci LLC
Aurinia Pharmaceuticals Inc
Bio-Path Holdings Inc
Biogen Inc
Biotest AG
Boehringer Ingelheim GmbH
Boston Pharmaceuticals Inc
Bristol-Myers Squibb Co
Carna Biosciences Inc
Celgene Corp
Cells for Cells SA
Corestem Inc
CuraVac Inc
Deltanoid Pharmaceuticals Inc
Domainex Ltd
Eisai Co Ltd
Eli Lilly and Co
Epsilon-3 Bio Ltd
F. Hoffmann-La Roche Ltd
Galapagos NV
Genentech Inc
Genosco Inc
Genovax Srl
Gilead Sciences Inc
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd
HanAll Biopharma Co Ltd
Hanmi Pharmaceuticals Co Ltd
Idorsia Ltd
Immungenetics AG
Immunomedics Inc
Immunwork Inc
Immupharma Plc
Invion Ltd
Janus Biotherapeutics Inc
Johnson & Johnson
K-Stemcell Co Ltd
Kezar Life Sciences Inc
Kyowa Hakko Kirin Co Ltd
Lead Discovery Center GmbH
LSK BioPartners Inc
MedAnnex Ltd
MedImmune LLC
Merck & Co Inc
Merck KGaA
Millennium Pharmaceuticals Inc
Mount Tam Biotechnologies Inc
Nektar Therapeutics
Neovacs SA
Nippon Chemiphar Co Ltd
Novartis AG
Nuevolution AB
Omeros Corp
Pfizer Inc
Ra Pharmaceuticals Inc
RedHill Biopharma Ltd
Regen BioPharma Inc
Sarepta Therapeutics Inc
SBI Biotech Co Ltd
Takeda Pharmaceutical Co Ltd
TheraMAB LLC
UCB SA
Xencor Inc
XTL Biopharmaceuticals Ltd
Zai Lab Ltd
2
Introduction 6
Systemic Lupus Erythematosus - Overview 7
Systemic Lupus Erythematosus - Therapeutics Development 8
Systemic Lupus Erythematosus - Therapeutics Assessment 24
Systemic Lupus Erythematosus - Companies Involved in Therapeutics Development 36
Systemic Lupus Erythematosus - Drug Profiles 69
Systemic Lupus Erythematosus - Dormant Projects 415
Systemic Lupus Erythematosus - Discontinued Products 422
Systemic Lupus Erythematosus - Product Development Milestones 424
Appendix 432List of Tables
Number of Products under Development for Systemic Lupus Erythematosus, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Systemic Lupus Erythematosus - Pipeline by AbbVie Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by ACEA Biosciences Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by AiCuris GmbH & Co KG, H1 2018
Systemic Lupus Erythematosus - Pipeline by Amgen Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Apellis Pharmaceuticals Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Araim Pharmaceuticals Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Asahi Kasei Pharma Corp, H1 2018
Systemic Lupus Erythematosus - Pipeline by Atlantic Bio Sci LLC, H1 2018
Systemic Lupus Erythematosus - Pipeline by Aurinia Pharmaceuticals Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Bio-Path Holdings Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Biogen Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Biotest AG, H1 2018
Systemic Lupus Erythematosus - Pipeline by Boehringer Ingelheim GmbH, H1 2018
Systemic Lupus Erythematosus - Pipeline by Boston Pharmaceuticals Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Bristol-Myers Squibb Co, H1 2018
Systemic Lupus Erythematosus - Pipeline by Carna Biosciences Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Celgene Corp, H1 2018
Systemic Lupus Erythematosus - Pipeline by Cells for Cells SA, H1 2018
Systemic Lupus Erythematosus - Pipeline by Corestem Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by CuraVac Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Deltanoid Pharmaceuticals Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Domainex Ltd, H1 2018
Systemic Lupus Erythematosus - Pipeline by Eisai Co Ltd, H1 2018
Systemic Lupus Erythematosus - Pipeline by Eli Lilly and Co, H1 2018
Systemic Lupus Erythematosus - Pipeline by Epsilon-3 Bio Ltd, H1 2018
Systemic Lupus Erythematosus - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
Systemic Lupus Erythematosus - Pipeline by Galapagos NV, H1 2018
Systemic Lupus Erythematosus - Pipeline by Genentech Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Genosco Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Genovax Srl, H1 2018
Systemic Lupus Erythematosus - Pipeline by Gilead Sciences Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by GlaxoSmithKline Plc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Glenmark Pharmaceuticals Ltd, H1 2018
Systemic Lupus Erythematosus - Pipeline by HanAll Biopharma Co Ltd, H1 2018
Systemic Lupus Erythematosus - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018
Systemic Lupus Erythematosus - Pipeline by Idorsia Ltd, H1 2018
Systemic Lupus Erythematosus - Pipeline by Immungenetics AG, H1 2018
Systemic Lupus Erythematosus - Pipeline by Immunomedics Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Immunwork Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Immupharma Plc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Invion Ltd, H1 2018
Systemic Lupus Erythematosus - Pipeline by Janus Biotherapeutics Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Johnson & Johnson, H1 2018
Systemic Lupus Erythematosus - Pipeline by K-Stemcell Co Ltd, H1 2018
Systemic Lupus Erythematosus - Pipeline by Kezar Life Sciences Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2018
Systemic Lupus Erythematosus - Pipeline by Lead Discovery Center GmbH, H1 2018
Systemic Lupus Erythematosus - Pipeline by LSK BioPartners Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by MedAnnex Ltd, H1 2018
Systemic Lupus Erythematosus - Pipeline by MedImmune LLC, H1 2018
Systemic Lupus Erythematosus - Pipeline by Merck & Co Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Merck KGaA, H1 2018
Systemic Lupus Erythematosus - Pipeline by Millennium Pharmaceuticals Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Mount Tam Biotechnologies Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Nektar Therapeutics, H1 2018
Systemic Lupus Erythematosus - Pipeline by Neovacs SA, H1 2018
Systemic Lupus Erythematosus - Pipeline by Nippon Chemiphar Co Ltd, H1 2018
Systemic Lupus Erythematosus - Pipeline by Novartis AG, H1 2018
Systemic Lupus Erythematosus - Pipeline by Nuevolution AB, H1 2018
Systemic Lupus Erythematosus - Pipeline by Omeros Corp, H1 2018
Systemic Lupus Erythematosus - Pipeline by Pfizer Inc, H1 2018List of Figures
Number of Products under Development for Systemic Lupus Erythematosus, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018
Research Methodology
The research study released with title "Systemic Lupus Erythematosus - Pipeline Review, H1 2018" involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.Key Executives Interviewed
Research Programs/Design
| Historical Data (2017-2022E) |
|
|
| Market Factor Analysis |
|
|
| Market Forecast (2023F-2028F) |
|
|
Market Size Estimation
Top-down and bottom-up approaches are used to validate and estimate the global/regional market size by manufacturers, regional splits, product segments and application.
To establish Research coverage of the study with most relevant & functional players HTF MI follows industry standards such as NAICS/SIC/ICB/TRCB, furthermore the sorted list of companies is validated using Product Mapping and business activities and shortlisted by industry perspective.
HTF MI select experienced analyst and associate that are specialized in the domain for conducting research. They prepare a list of companies by region that helps to understand players penetration rate in the market. This companies are further analyses in what segment or application they serve in our market. The list of product and applications are evaluated for each companies dealing in the Systemic Lupus Erythematosus Pipeline Review outlook. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global. Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Online) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc from Systemic Lupus Erythematosus Pipeline Review outlook who then work towards appointment generation.
Primary Data Collection
The primary research is performed by taking the interviews of executives of various companies dealing in the Systemic Lupus Erythematosus Pipeline Review outlook as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and relevant list of appointee or target primary respondents; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & In Mail, Community Forums, Open Survey, SurveyMonkey etc.
Secondary Sources
The secondary resources considered in the Systemic Lupus Erythematosus Pipeline Review outlook study includes company annual reports, press releases, published articles of organizations and associations, and the survey taken through different mediums such as online website and forums, survey monkey, LinkedIn, etc. In addition, the valuable strategic information obtained from industry association, paid database, and investor presentations are also good tool for information to make appropriate iterative validation are used to modify market models and cross-verify primary research and insights.
Market Breakdown and Data Triangulation
To make market engineering data complete; extensive primary research is conducted to gather information and validate the critical numbers derived to be used for calculations of market statistics; market size estimations; forecasting; breakdown; and data triangulation. Both top-down and bottom-up approaches were applied, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report. Furthermore qualitative and further quantitative analysis is also done for all the numbers arrived at in the market estimation process to list relevant information in the final deliverable report "Systemic Lupus Erythematosus - Pipeline Review, H1 2018" .
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Key Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments |
|
|
| Total Market |
|
|
| Format | Properties | |
|---|---|---|
| 1-User Access | The report is sent in PDF format. The report will be emailed to you. | This is a single user access license, allowing one specific user to access the report. |
| Site User | The study would be provided in PDF format. The report will be emailed to you. | This is a site license, allowing 1-10 employees within your organisation to access the report. |
| Enterprise User | The format of deliverable would be PDF and Excel. | This is an enterprise or corporate license, allowing all employees within your organisation irrespective of geographic location to access the report. |
